Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
Bridging the gap in paediatric sickle cell care: Expanding transplant access globally
JOURNALS
Start Learning
Greatest Hits of 2024
JOURNALS
Start Learning
A legacy in haematology: Prof. Robin Foà’s path from paediatrics to global impact
CONFERENCE HUB
Start Learning
Very early FDG-PET/CT response-adapted therapy for advanced Hodgkin lymphoma
CONFERENCE HUB
Start Learning
Key highlights from ASH 2024: Promising new therapies for relapsed/refractory acute myeloid leukaemia
CONFERENCE HUB
Start Learning
Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024
Combination Therapy in Myelofibrosis: John Mascarenhas on the IMpactMF trial
JOURNALS
Start Learning
Combination therapy in myelofibrosis: John Mascarenhas on the IMpactMF trial
touchFEATURE
Start Learning
Isatuximab demonstrated consistent PFS benefits across diverse patient profiles in RRMM in 2 pivotal trials
Sponsored content
touchCONGRESS
Start Learning
Updates in BCMA-directed therapies in multiple myeloma from ASH 2024
CE/CME ACCREDITED
CONFERENCE HUB
Start Learning
Durable clinical benefit with elritercept in lower-risk MDS: KER050-MD-201 trial

to view Favourites, Keep Notes and Track CME Credits

Favourites
ISTH unveils new guidelines for haemophilia treatment
View
Novel CD7-targeted CAR T-cell therapy elicits strong responses in relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
View
#ASH24: The countdown is on!
View
BVd compared to DVd in RRMM: The DREAMM-7 trial
View
#ASH24: Discover the 2024 late-breaking abstracts
View
Collaboration in chronic ITP: Improving quality of life and patient outcomes
View
A legacy in haematology: Prof. Robin Foà’s path from paediatrics to global impact
View
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
View
EHA 2024: Highlights of the late-breaking abstracts
View
Should we intensify chemotherapy in the treatment of acute myeloid leukemia? Insights from ASH 2024
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup